The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The Pharmacology of Longevity: Peptide Edition (Part 1) Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means The Blacklisting of Peptides Orthopedic Use of BPC 157 Sports Med Review FDA's new guidelines on bulk drug compounding Pharmacy & Healthcare Legal Blog